

This article has been accepted for publication in ARD following peer review.  
The definitive copyedited, typeset version is available online at [10.1136/annrheumdis](https://doi.org/10.1136/annrheumdis)

## European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE Classification Criteria Item Performance

Martin Aringer, Ralph Brinks, Thomas Dörner, David I. Daikh, Marta Mosca, Rosalind Ramsey-Goldman, Josef S. Smolen, David Wofsy, Dimitrios Boumpas, Diane L. Kamen, David Jayne, Ricard Cervera, Nathalie Costedoat-Chalumeau, Betty Diamond, Dafna D. Gladman, Bevra H. Hahn, Falk Hiepe, Søren Jacobsen, Dinesh Khanna, Kirsten Lerstrøm, Elena Massarotti, W. Joseph McCune, Guillermo Ruiz-Irastorza, Jorge Sanchez-Guerrero, Matthias Schneider, Murray B. Urowitz, George Bertsias, Bimba F. Hoyer, Nicolai Leuchten, Gabriela Schmajuk, Chiara Tani, Sara K. Tedeschi, Zahi Touma, Branimir Anic, Florence Assan, Tak Mao Chan, Ann E. Clarke, Mary K. Crow, László Czirják, Andrea Doria, Winfried B. Graninger, Bernadett Halda-Kiss, Sarfaraz Hasni, Peter Izmirly, Michelle Jung, Gábor Kumánovics, Xavier Mariette, Ivan Padjen, José M. Pego-Reigosa, Juanita Romero-Díaz, Iñigo Rúa-Figueroa Fernández, Raphaële Seror, Georg Stummvoll, Yoshiya Tanaka, Maria G. Tektonidou, Carlos Vasconcelos, Edward M. Vital, Daniel Wallace, Sule Yavuz, Pier Luigi Meroni, Marvin J Fritzler, Ray P. Naden†, Karen H. Costenbader, Sindhu R. Johnson.

†We mourn Prof. Ray Naden, who passed away on August 16<sup>th</sup>, 2020. The authors wish to dedicate this article to his memory as a friend and colleague, and to highlight his efforts for these and other criteria.

**Correspondence to:** Prof Martin Aringer, Rheumatology, Medicine III, University Medical Center TU Dresden, Fetscherstrasse 74, 01307 Dresden, Germany; [martin.aringer@uniklinikum-dresden.de](mailto:martin.aringer@uniklinikum-dresden.de), and Dr Sindhu R Johnson, Division of Rheumatology, Ground Floor, East Wing, Toronto Western Hospital, 399 Bathurst Street, Toronto, ON M5T2S8, Canada; [Sindhu.Johnson@uhn.ca](mailto:Sindhu.Johnson@uhn.ca).

Martin Aringer MD, University Medical Center and Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany

Ralph Brinks PhD, Policlinic and Hiller Research Unit for Rheumatology, Medical Faculty, Heinrich-Heine-University Duesseldorf, Duesseldorf, Germany

Thomas Dörner MD, Charité – Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, Berlin, Germany

David I. Daikh MD PhD, Oregon Health and Sciences University and Portland VA Health Care System, Portland, OR, USA

Marta Mosca MD PhD, Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana, University of Pisa, Pisa, Italy

Rosalind Ramsey-Goldman MD DrPH, Northwestern University Feinberg School of Medicine, Chicago, IL, USA

Josef S. Smolen MD, Medical University of Vienna, Austria

David Wofsy MD, Russell/Engleman Rheumatology Research Center, University of California at San Francisco, San Francisco, USA

Dimitrios Boumpas MD, Medical School, National and Kapodestrian University of Athens, and Biomedical Research Foundation of the Athens Academy, Athens, Greece; Medical School, University of Cyprus, Nicosia, Cyprus.

Diane L. Kamen MD MSCR, Medical University of South Carolina, Charleston, SC, USA

David Jayne MD FRCP FRCPE FMedSci, Department of Medicine, University of Cambridge, United Kingdom

Ricard Cervera MD PhD FRCP, Department of Autoimmune Diseases, Hospital Clínic, University of Barcelona, Barcelona, Catalonia, Spain

Nathalie Costedoat-Chalumeau, MD PhD AP-HP, Cochin Hospital, Internal Medicine Department, Centre de référence maladies auto-immunes et systémiques rares d'île de France, Paris, France ; Université Paris Descartes-Sorbonne Paris Cité, Paris, France ; INSERM U 1153, Center for Epidemiology and Statistics Sorbonne Paris Cité (CRESS), Paris, France

Betty Diamond MD, Feinstein Institute, Manhasset, NY, United States

Dafna D. Gladman, MD FRCPC, Division of Rheumatology, Department of Medicine, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada

Bevra H Hahn MD, University of California at Los Angeles, Los Angeles, CA, USA

Falk Hiepe MD, Charité – Universitätsmedizin Berlin, Corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Department of Rheumatology and Clinical Immunology, Berlin, Germany

Søren Jacobsen MD DMSc, Copenhagen Lupus and Vasculitis Clinic, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark

Dinesh Khanna MD MS, University of Michigan, Ann Arbor, MI, USA

Kirsten Lerstrøm, Lupus Europe, co-opted trustee for research, Essex, UK

Elena Massarotti MD, Brigham and Women's Hospital, Boston MA; Harvard Medical School, Boston, USA

W. Joseph McCune MD, University of Michigan, Ann Arbor, MI, USA

Guillermo Ruiz-Irastorza MD PhD, Autoimmune Diseases Research Unit, Department of Internal Medicine, Biocruces Bizkaia Health Research Institute, Hospital Universitario Cruces, UPV/EHU, Bizkaia, The Basque Country, Spain

Jorge Sanchez-Guerrero MD MSc, Division of Rheumatology, Department of Medicine Mount Sinai Hospital/University Health Network, University of Toronto, Toronto, Ontario, Canada; and Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

Matthias Schneider MD, Policlinic and Hiller Research Unit for Rheumatology, Medical Faculty, Heinrich-Heine-University, Düsseldorf, Germany

Murray B. Urowitz MD, Division of Rheumatology, Department of Medicine, Toronto Western Hospital, University of Toronto, Toronto, Ontario, Canada

George Bertias MD, Rheumatology, Clinical Immunology and Allergy, University of Crete Medical School, Heraklion, Greece; and Institute of Molecular Biology-Biotechnology, Foundation for Research and Technology - Hellas (FORTH), Heraklion, Greece

Bimba F. Hoyer MD, Department of Rheumatology and Clinical Immunology, University Hospital of Schleswig-Holstein at Kiel, Kiel, Germany

Nicolai Leuchten MD, University Medical Center and Faculty of Medicine Carl Gustav Carus, TU Dresden, Dresden, Germany

Gabriela Schmajuk MD MS, University of California at San Francisco and the VA Medical Center, San Francisco, USA

Chiara Tani MD, Rheumatology Unit, Azienda Ospedaliero Universitaria Pisana, University of Pisa, Pisa, Italy

Sara K. Tedeschi MD MPH, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

Zahi Touma, MD PhD, Division of Rheumatology, Department of Medicine, Toronto Western Hospital, Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada

Branimir Anic MD, Division of Clinical Immunology and Rheumatology, University of Zagreb School of Medicine and University Hospital Centre Zagreb, Zagreb, Croatia

Florence Assan MD, Université Paris-Saclay, INSERM, CEA, Centre de recherche en Immunologie des infections virales et des maladies auto-immunes ; AP-HP. Université Paris Saclay, Hôpital Bicêtre, Rheumatology ; 94270, Le Kremlin Bicêtre, France.

Tak Mao Chan MD, University of Hong Kong, Hong Kong

Ann E. Clarke MD MSc, Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada

Mary K. Crow MD, Hospital for Special Surgery, New York, NY, USA

László Czirják MD, University of Pécs, Medical School, Pécs, Hungary

Andrea Doria MD, Rheumatology Unit, Department of Medicine (DIMED), University of Padova, Padova, Italy

Winfried B. Graninger MD, Medical University of Graz, Graz, Austria

Bernadett Halda-Kiss MD, University of Pécs, Medical School, Pécs, Hungary

Sarfaraz Hasni MD, NIAMS, NIH, Bethesda, MD

Peter Izmirly MD, New York University School of Medicine, New York, New York, USA

Michelle Jung, University of Calgary, Calgary, Alberta, Canada

Gábor Kumánovics MD, University of Pécs Medical School, Pécs, Hungary

Xavier Mariette MD PhD, Université Paris-Saclay, INSERM, CEA, Centre de recherche en Immunologie des infections virales et des maladies auto-immunes ; AP-HP.Université Paris Saclay, Hôpital Bicêtre, Rheumatology ; 94270, Le Kremlin Bicêtre, France

Ivan Padjen MD, Division of Clinical Immunology and Rheumatology, University of Zagreb School of Medicine and University Hospital Centre Zagreb, Zagreb, Croatia

José M. Pego-Reigosa MD PhD, Department of Rheumatology, University Hospital of Vigo, IRIDIS Group, Instituto de Investigación Sanitaria Galicia Sur (IISGS), Vigo, Spain

Juanita Romero-Díaz MD, , MSc, Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico

Iñigo Rúa-Figueroa Fernández MD, Hospital Dr Negrin, Las Palmas, Spain

Raphaèle Seror MD, PhD, Université Paris-Saclay, INSERM, CEA, Centre de recherche en Immunologie des infections virales et des maladies auto-immunes ; AP-HP.Université Paris Saclay, Hôpital Bicêtre, Rheumatology ; 94270, Le Kremlin Bicêtre, France.

Georg Stummvoll MD, Medical University of Vienna, Vienna, Austria

Yoshiya Tanaka MD PhD, University of Occupational & Environmental Health, Kitakyushu, Japan

Maria G. Tektonidou MD PhD, Medical School, National and Kapodistrian University of Athens, Athens, Greece

Carlos Vasconcelos MD PhD, Centro Hospitalar do Porto, ICBAS, UMIB, University of Porto, Porto, Portugal

Edward M Vital MRCP PhD, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds; NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom

Daniel J. Wallace MD, Cedars-Sinai, Los Angeles, CA, USA

Sule Yavuz MD, Istanbul Bilim University, Istanbul Florence Nightingale Hospital, Istanbul, Turkey

Pier Luigi Meroni MD, Clinical Immunology and Rheumatology Unit, IRCCS Istituto Auxologico Italiano, Milan, Italy

Marvin J Fritzler PhD MD, Faculty of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada

Ray P. Naden MB ChB FRACP, Department of Medicine, McMaster University, Hamilton, Ontario, Canada

Karen H. Costenbader MD MPH, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA

Sindhu R. Johnson MD PhD FRCPC, Division of Rheumatology, Department of Medicine, Toronto Western Hospital, Mount Sinai Hospital; Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, Ontario, Canada



## Abstract

**Background/Objectives** The EULAR/ACR 2019 classification criteria for systemic lupus erythematosus system showed high specificity, while attaining also high sensitivity. We hereby analyzed the performance of the individual criteria items and their contribution to the overall performance of the criteria.

**Methods** We combined the EULAR/ACR derivation and validation cohorts for a total of 1,197 SLE and n=1,074 non-SLE patients with a variety of conditions mimicking SLE, such as other autoimmune diseases, and calculated the sensitivity and specificity for anti-nuclear antibodies (ANA) and the 23 specific criteria items. We also tested performance omitting the EULAR/ACR criteria attribution rule, which defines that items are only counted if not more likely explained by a cause other than SLE.

**Results** Positive ANA, the new entry criterion, was 99.5 % sensitive, but only 19.4% specific, against a non-SLE population that included other inflammatory rheumatic, infectious, malignant and metabolic diseases. The specific criteria items were highly variable in sensitivity (from 0.42% for delirium and 1.84% for psychosis to 75.6% for antibodies to double-stranded DNA), but their specificity was uniformly high, with low C3 or C4 (83.0%) and leucopenia  $<4.000/\text{mm}^3$  (83.8%) at the lowest end. Unexplained fever was 95.3% specific in this cohort. Applying the attribution rule improved specificity, particularly for joint involvement.

**Conclusions** Changing the position of the highly sensitive, non-specific ANA to an entry criterion and the attribution rule resulted in a specificity of  $>80\%$  for all items, explaining the higher overall specificity of the criteria set.

## Key words

Systemic lupus erythematosus, classification criteria, specificity, anti-nuclear antibodies, lupus arthritis

## Key messages

### What is already known about this subject?

The EULAR/ACR 2019 classification criteria for SLE have higher sensitivity than the ACR criteria, but maintained high specificity.

### What does this study add?

In the combined EULAR/ACR derivation and validation cohorts, which contained large groups of patients with other connective tissue diseases in the non-SLE population, ANA had high sensitivity, but only 19.4% specificity.

The most important factors for the increase in specificity of the EULAR/ACR criteria were the shifting of ANA to the position of an entry criterion, and the attribution rule, by which items count towards SLE only if there is no more likely alternative explanation.

Fever, the entirely new item in the EULAR/ACR criteria, had a sensitivity of 14.8% and a specificity of 95.3% for SLE.

### How might this impact on clinical practice?

While the EULAR/ACR classification criteria should not be used as diagnostic criteria, the findings are applicable to the diagnostic process: ANA are a useful screening test, but not specific for SLE. Other symptoms should only be attributed to SLE if there is no more likely other diagnosis found. This of course applies to fever, which, if otherwise unexplained, is an argument for SLE.

The most relevant performance characteristics of any classification criteria are sensitivity and specificity of the whole set of criteria in a relevant validation cohort. Accordingly, for the European League Against Rheumatism (EULAR)/ American College of Rheumatology (ACR) 2019 classification criteria for systemic lupus erythematosus (SLE), these data were reported in the joint publication(1;2) together with comparative sensitivity and specificity values of the ACR 1997 and the Systemic Lupus International Collaborating Clinics (SLICC) 2012 criteria systems.

The EULAR/ACR classification criteria project comprised four phases.(1;2;8) Phase 1 evaluated ANA as an entry criterion(9) and generated criteria items in an expert Delphi exercise,(10) an international early SLE cohort(11) and an SLE patient survey.(12) Phase 2 reduced the number of items in a nominal group technique exercise,(13) evaluated the interdependency of items in a two-step association study(14) and precisely defined the remaining items.(7) Phase 3 grouped the items and derived an individual weight for each item, based on a multicriteria decision analysis.(15) Phase 4 relied on a large international cohort collected worldwide, and split into a derivation and a validation cohort.(1;2) This cohort contains data from a total of 1,197 SLE patients and 1,074 non-SLE patients.

The EULAR/ACR 2019 criteria require a positive anti-nuclear antibody (ANA) test with a titer of  $\geq 1:80$  by HEp-2 immunofluorescence or equivalent at any time as an obligatory entry criterion. For ANA positive patients, criteria ordered in seven clinical and three immunological domains are applied according to specific weights. A total sum score of 10 or more allows for classification as SLE. Criteria items count only if there is no more likely explanation than SLE. As in previous criteria systems, at least one clinical item is required, and historically positive items count. With these features, the EULAR/ACR 2019 criteria achieved about as high a specificity as the 1997 updated ACR criteria(3) and still as high a sensitivity as the 2012 SLICC criteria,(4) with an improved combined specificity and sensitivity as compared to the previous criteria.(1;2) These characteristics are maintained across sexes and ethnicities and in those with early disease.(5)

While the performance of the individual items was not reported, the information on their sensitivity and specificity may be highly instructive. Indeed, individual criterion performance characteristics of the ACR 1982(6) and SLICC 2012(4) criteria were considered in the EULAR/ACR criteria approach, particularly in its early phases.(7) For example, the strategic decision to evaluate repositioning ANA as an entry criterion(8) was influenced by these data. Here we present the sensitivity and specificity analysis of the EULAR/ACR criteria individual items.

## **Patients and Methods**

**Subjects.** Data on the 1982 ACR patient database(6) and 2012 SLICC derivation cohort(4) were taken from the respective publications. For the analysis of the EULAR/ACR international patient cohort, the derivation and validation cohorts were combined. To this cohort, every center contributed up to 100 SLE cases and 100 non-SLE cases with conditions mimicking SLE.(1;2) SLE diagnosis was used as a gold standard. Diagnoses of non-SLE control subjects included other connective tissue diseases (62.6%), other rheumatic and musculoskeletal diseases (28.7%), cancer, membranous nephritis, and chronic infections (online supplementary Table 1). A standardized form containing all items of the EULAR/ACR, SLICC and ACR criteria sets was used to collect data on all cases and controls. All laboratory tests, including ANA and SLE-specific autoantibodies, were performed locally, according to the submitting center's laboratory standards. The diagnoses of SLE vs non-SLE were triple-confirmed by independent investigators. Where needed, this procedure involved several steps, including direct queries. Cases were only included if the submitting center and all three external investigators agreed.(1;2) Sixty-eight cases (2.9 %) were excluded due to lack of consensus on the diagnosis. The cohorts were comprised of the 1,197 triple-confirmed SLE cases and 1,074 triple-confirmed non-SLE cases.(1;2) Ethics committee approval and subject consent were obtained as per local requirements.

**Analyses.** The sensitivity and specificity of the individual items were evaluated using the EULAR/ACR criteria attribution rule. In an additional analysis, sensitivities and specificities were evaluated without the EULAR/ACR criteria attribution rule. The attribution rule states that items shall only be counted if there were no more likely explanation than SLE. This rule would for example preclude counting arthritis in a patient with rheumatoid arthritis (RA) for SLE. Sensitivity was calculated as the proportion of SLE patients (truly) positive for a criterion in the whole cohort, specificity as the proportion of all non-SLE patients negative for a criterion. Confidence intervals (CI) were calculated using the bias-corrected and accelerated bootstrap method (BCa method) with B=2000 bootstrap samples.(1;2)

## Results

**Specificity of individual items.** With the anticipated exception of the entry criterion of a positive ANA, which had a very high sensitivity of 99.5 %, but a low specificity of only 19.4%, all criteria items had a specificity of at least 80% (Table 1). In fact, only three items had a specificity lower than 90%, namely low complement C3 or C4 (83.0%), leucopenia (83.8%) and positive antiphospholipid antibodies (87.7%). The limited specificity appeared almost exclusively due to their prevalence in other conditions, such as primary antiphospholipid syndrome and primary Sjögren's syndrome, which were included in the non-SLE cohorts (see online supplementary Table 1). Of relevance, these items were also assigned relatively low weights of 2 or 3 (Table 1). The 95% confidence intervals are shown in online supplementary Table 2.

**Sensitivity of individual items.** As expected, given that the goal of the new criteria set was to maximize the specificity for SLE, the differences in sensitivity were greater than those for specificity. Even when not taking the entry criterion of positive ANA into account, sensitivity ranged from as high as 75.6% for antibodies to double-stranded DNA (dsDNA), 72.0% for joint involvement, and 71.7% for low C3 or C4 to as low as 1.84% for psychosis and 0.42% for delirium. An acute cutaneous LE (ACLE) rash was seen in 42.8%, 10.9% had a subacute cutaneous LE (SCLE) and 8.4% a discoid rash, while 35.5% had non-scarring alopecia and 27.0% oral ulcers. One third of the SLE patients had proteinuria, with class III or IV nephritis more than twice as common as class II or V nephritis (Table 1). Pleural and/or pericardial effusions were found in 16.0%, and 14.8% had non-infectious fever.

**Sensitivity plus specificity.** Based on these data, despite the low sensitivity of some items, every single item has a combined sensitivity plus specificity of >1.0, ranging from 1.004 for delirium to 1.693 for specific antibodies to double-stranded DNA.



**Table 1.** Relative item weight, number of SLE and non-SLE patients fulfilling and not fulfilling the individual EULAR/ACR criteria items and the resulting sensitivities and specificities.

Criterion	weight	n=1,197 SLE		n=1,074 Non-SLE		Sensitivity	Specificity
		positive	negative	positive	negative		
ANA (entry criterion)		1,191	6	866	208	99.5%	19.4%
Fever	2	177	1,020	51	1023	14.8%	95.3%
Leucopenia	3	574	623	174	900	48.0%	83.8%
Thrombocytopenia	4	190	1,007	44	1,030	15.9%	95.9%
Autoimmune hemolysis	4	53	1,144	1	1,073	4.4%	99.9%
Delirium	2	5	1,192	0	1,074	0.4%	100.0%
Psychosis	3	22	1,175	0	1,074	1.8%	100.0%
Seizure	5	60	1,137	8	1,066	5.0%	99.3%
Alopecia	2	425	772	63	1,011	35.5%	94.1%
Oral ulcers	2	323	874	75	999	27.0%	93.0%
Discoid LE	4	100	1,097	3	1,071	8.4%	99.7%
SCLE	4	131	1,066	3	1,071	10.9%	99.7%
ACLE	6	512	685	12	1,062	42.8%	98.9%
Pleural/pericardial effusion	5	192	1,005	34	1,040	16.0%	96.8%
Acute pericarditis	6	61	1,136	11	1,063	5.1%	99.0%
Joint involvement	6	862	335	98	976	72.0%	90.9%
Proteinuria	4	398	799	11	1,063	33.3%	99.0%
Class II/V nephritis	8	124	1,073	2	1,072	10.4%	99.8%
Class III/IV nephritis	10	262	935	1	1,073	21.9%	99.9%
Antiphospholipid ab.	2	315	882	132	942	26.3%	87.7%
C3 or C4 low	3	858	339	183	891	71.7%	83.0%
C3 and C4 low	4	554	643	48	1,026	46.3%	95.5%
Anti-dsDNA ab.	6	905	292	68	1,006	75.6%	93.7%
Anti-Sm ab.	6	282	915	9	1,065	23.6%	99.2%

ab. antibody.

**Comparison with the ACR 1982 and SLICC 2012 data sets.** We compared the sensitivity and specificity data with those of the ACR 1982 criteria(6) and the SLICC 2012 criteria(4), in as much as these data have been reported. Fever, acute pericarditis, the separate categories of class III/IV and class II/V lupus nephritis and low C3 and C4 were items newly defined within the EULAR/ACR classification criteria project(7) and could therefore not be compared. For some of the other variables (e.g. delirium), data are reported only for the whole (neurologic) criterion in the SLICC data set, and therefore likewise not available for comparison. As shown in Table 2, most of the available values were in a similar range. However, there was a difference in the specificity of arthritis, which was reported as 37% for the ACR and 43.6 % for the SLICC criteria systems, but 90.9% in the EULAR/ACR 2019 system, using the SLICC criteria definition. When the same data were analyzed without the attribution rule, specificity fell to 57.6 %, much closer to the range of the previous sets (Table 2, right column).

**Table 2.** Sensitivities and specificities of individual items in comparison with the data reported in the ACR 1982 classification criteria and SLICC 2012 classification criteria manuscripts. For the EULAR/ACR 2019 criteria system, the left two columns depict data attributed per EULAR/ACR classification criteria attribution rule, while the right two columns show data when the attribution rule was deliberately omitted\*. Data are only shown for items with alternative explanations captured in the cohort; if no numbers are shown the resulting numbers were identical to the columns with the attribution rule applied.

Criterion	ACR 1982		SLICC 2012		EULAR/ACR 2019			
	Sens	Spec	Sens	Spec	Attribution rule applied			
					Yes		No*	
	Sens	Spec	Sens	Spec	Sens	Spec	Sens	Spec
ANA (entry criterion)	99 %	49 %	96.5 %	45.2 %	NA	NA	99.5 %	19.4 %
Leucopenia‡	46 %	89 %	46.4 %	94.8 %	48.0 %	83.8 %		
Thrombocytopenia‡	21 %	99 %	13.5 %	98.0 %	15.9 %	95.9 %		
Autoimmune hemolysis‡	18 %	99 %	7.1 %	99.5 %	4.4 %	99.9 %		
Psychosis	13 %	99 %	NR§	NR§	1.8 %	100 %		
Seizure	12 %	99 %	NR§	NR§	5.0 %	99.3 %		
Alopecia	NR	NR	31.9 %	95.7 %	35.5 %	94.1 %		
Oral ulcers‡	27 %	96 %	44.2 %	92.1 %	27.0 %	93.0 %		92.4 %
Discoid LE‡	18 %	99 %	19.7 %	93.6 %	8.4 %	99.7 %		
SCLE‡	NR	NR	NR§	NR§	10.9 %	99.7 %		
ACLE‡	57 %	96 %	65.2 %	80.1 %	42.8 %	98.9 %		
Pleural/pericardial effusion‡	56 %	86 %	35.2 %	97.2 %	16.0 %	96.8 %		
Joint involvement‡	86 %	37 %	79.0 %	43.6 %	72.0 %	90.9 %	72.4 %	57.6 %
Proteinuria	51 %	94 %	32.9 %	46.4 %	33.3 %	99.0 %		96.1 %
Antiphospholipid ab.	NR	NR	53.5 %	86.0 %	26.3 %	87.7 %		
C3 or C4 low	NR	NR	59.0 %	92.6 %	71.7 %	83.0 %		
Anti-dsDNA ab.‡	67 %	92 %	57.1 %	95.9 %	75.6 %	93.7 %		
Anti-Sm ab.	31 %	95 %	26.1 %	98.7 %	23.6 %	99.2 %		

NR not reported. ab. antibody. ‡ Different item definitions used. § The SLICC criteria 2012 manuscript reports data on ACLE plus SCLE and on the complete neuropsychiatric domain only.

**Role of correct attribution.** We analyzed the role of the attribution rule for all EULAR/ACR classification criteria items. As shown in Table 3, which is ordered by the size of the change, arthritis was most affected by correctly attributing this symptom to the more likely explanation, which was most commonly RA. Other items that were less affected were fever, proteinuria, oral ulcers (e.g. Behçet’s disease), and acute pericarditis. The remaining items were not affected. Had the attribution rule not been applied, the numbers of SLE patients for whom items would have been counted, i.e. the sensitivity of the items, would only have relevantly increased for fever, and marginally for joint involvement (Table 3). Neuropsychiatric symptoms, including delirium, seizures and psychosis, may also be due to an underlying disease process other than SLE.

**Table 3.** Influence of correctly applying the EULAR/ACR criteria attribution rule on individual items, ordered by magnitude of the effect. While the effects on the number of SLE patients with these criteria fulfilled were minimal (left columns), specificity did change for several items (right columns).

Criterion	n=1,197 SLE				n=1,074 Non-SLE					
	Applied		Not applied		Applied			Not applied		
	pos	neg	pos	neg	pos	neg	Spec	pos	neg	Spec
Joint involvement	862	335	866	331	98	976	<b>90.9%</b>	455	619	<b>57.6%</b>
Fever	177	1,020	226	971	51	1,023	<b>95.3%</b>	89	985	<b>91.7%</b>
Proteinuria	398	799	398	799	11	1,063	<b>99.0%</b>	42	1,032	<b>96.1%</b>
Oral ulcers	323	874	323	874	75	999	<b>93.0%</b>	82	992	<b>92.4%</b>
Acute pericarditis	61	1,136	61	1,136	11	1,063	<b>99.0%</b>	14	1,060	<b>98.7%</b>

**Changes to low-specificity items in the EULAR/ACR classification criteria**

In addition to the impact of the attribution rule for increasing the specificity of the joint involvement criterion and the strategic shift in position of ANA positivity to an entry criterion, effectively eliminating an impact of its low specificity (19.4%), the exclusion of lymphopenia by the vote of the external experts in the nominal group technique exercise also influenced specificity (Table 4). Likewise, photosensitivity was not included, increasing the specificity of ACLE. Finally, for antiphospholipid antibodies, specificity remained at below 90 %, but this item has received a low weight,(15) carrying only 2 points.(1, 2) In contrast to the previous classification criteria sets, all items now reached >80 % specificity and most items had a specificity of 90 % or more (Table 1).

**Table 4.** Changes to items of (relatively) low specificity made in the course of the EULAR/ACR SLE classification criteria project.

Criterion	ACR 1982	SLICC 2012	EULAR/ACR 2019		
			Derivation	Validation	
			No attribution	Attribution	
	Specificity	Specificity	Specificity	Specificity	Specificity
ANA	49%	45.2%	19.4%	Entry criterion	
ACLE/Photosensitive rash	NR	80.1%	89.2%	No EULAR/ACR criterion	
ACLE	96%	NR	98.8%	98.8%	99.0%
Joint involvement	37%	43.6%	48.4%	86.6%	94.6%
Lymphopenia <1,500x10 <sup>9</sup> /L	NR	81.6%	72.2%	No EULAR/ACR criterion	
Lymphopenia <1,000x10 <sup>9</sup> /L	NR	94.7%	81.4%	No EULAR/ACR criterion	
Antiphospholipid ab.	NR	86.0%	88.6%	88.6%	86.9%

ab. antibody.

## Discussion

Our evaluation of individual items comprising the EULAR/ACR 2019 classification criteria and previous iterations of SLE classification criteria provides important insights. First, individual classification criteria items in the EULAR/ACR 2019 criteria system have relative homogeneity in specificity that was unprecedented in previous sets. Limiting the criteria set to relatively high specificity items improves overall specificity. Second, these data shed light on the differences in performance between the different criteria sets. Third, the current data highlight the prevalence of various organ manifestations in three different classification criteria cohorts over four decades.

These data on the individual items revealed that the EULAR/ACR 2019 classification criteria approach has led to relatively uniform specificities, ranging between 83 % and 100 %. In fact, all but three items had a specificity of 90% or higher. This is an important insight as classification criteria are only as strong as their weakest component.(18) Compared to the ACR(6) and SLICC(4) criteria systems, the most pronounced impact on specificity was found for ANA and joint involvement or arthritis. A positive ANA test result ranged in specificity between 19 % and 49 %. The particularly low specificity of positive ANA in the EULAR/ACR cohort is explained by the fact that almost two thirds of the non-SLE patients with conditions mimicking SLE had other connective tissue diseases. Positive ANA was strategically repositioned to constitute an obligatory entry criterion at a titer of  $\geq 1:80$ , after the high sensitivity of this test was reconfirmed.(9)

For joint involvement, the attribution rule of the EULAR/ACR criteria increased specificity. This attribution rule took the place of statements for each individual criterion regarding conditions that should not be scored. The ACR(6) and SLICC criteria(4), for example, defined thrombocytopenia “in the absence of offending drugs” and “in the absence of other known causes such as drugs, portal hypertension, and thrombotic thrombocytopenic purpura”, respectively, with such exclusions

defined for various items. The EULAR/ACR 2019 attribution rule defines for all items that they should only be counted for SLE if there is no more likely alternative explanation.(7) More likely alternative explanations also include other systemic autoimmune diseases. Rheumatoid arthritis, usually anti-cyclic citrullinated peptide positive, rheumatoid factor positive and erosive, was one of the examples used for illustrating this rule during the criteria process. RA was also one of the diseases specifically addressed, for allowing the classification of RA/SLE overlap (Rheupus) situations.(16;17) However, this attribution rule now increased the specificity from 58% to 91%.

SLE joint disease differs from RA in that frank palpable synovitis needs not be present. Indeed, in contrast to RA, ultrasonography provides a clear increase in sensitivity,(19) and the SLICC criteria definition was superior to palpable synovitis.(1,2,4) The new criteria set therefore employs the same definition as in the 2012 SLICC criteria system, and, from the EULAR/ACR review on, termed articular manifestations joint involvement instead of arthritis. Joint involvement was the most prevalent clinical item in all of the three sets. If anything, the percentage of patients with joint involvement declined slightly over time, from 86 % in the ACR via 79 % in the SLICC criteria to 72 % in the EULAR/ACR patient cohort. With most SLE patients having joint involvement, SLE needs to be in the differential diagnosis of symmetrical polyarthritis. Still, RA, for one example, is at least 10 times more common, reiterating the point of attribution made above.

The attribution rule also influenced the specificity of other criteria items, namely fever, proteinuria, oral ulcers, and acute pericarditis. Fever is one example, which must not be attributed to SLE when there is another, more likely explanation, such as infection. This will also affect sensitivity. Of 226 SLE patients with fever, only 177 (78%) had clear non-infectious fever best explained by SLE. In the non-SLE group, of 89 patients with fever, only 51 (57%) had no more likely other explanation, be it infections or other clearly febrile conditions, such as adult onset Still's disease (AODS) or familial Mediterranean fever (FMF). It is important to stress the cohort included a small number of patients with infection, which is not representative of the situation when patients are admitted with fever. Oral ulcers in 7 of 82 non-SLE patients were expectedly attributable to other diseases, such as Behçet's; and serositis was more likely attributed to causes like familial Mediterranean fever or tuberculosis in 3 of 14 non-SLE patients with acute pericarditis.

Finally, the highest weighted items also have very high specificity, while items with a specificity of less than 90% carry a maximum of 3 points (Table 1). The introduction of low complement levels by the SLICC group(4) was an important step. However, having either C3 or C4 low only showed a limited specificity of 83 %, which should also be taken into consideration for diagnostic purposes. In contrast, low values for both C3 and C4 increased the specificity to 96%.

There are some limitations to consider when analyzing changes in item sensitivity and specificity from this data set. These include different definitions, such as the definition of joint involvement, different cut-off values for hematology, and slightly different definitions for serositis and neuropsychiatric items. Temporal changes in pattern may still be of interest. The 1982 ACR criteria cohort(6) included almost 50 % of patients with lupus nephritis (by proteinuria); this percentage was lower and amounted to approximately one third for both the SLICC(4) and EULAR/ACR(1, 2) data sets. Oral ulcers stayed remarkably constant at 27 % sensitivity in the ACR and EULAR/ACR criteria. While ACLE lesions were found in approximately half of the patients throughout the cohorts, discoid LE was found in less than 10 % of the EULAR/ACR cohort patients, as compared to almost 20 % in the ACR and SLICC cohorts. In the EULAR/ACR cohort, SCLE was slightly more prevalent than discoid LE. Some of these changes may represent earlier disease and earlier interventions over time,(20) or differences in case selection between the cohorts. In the hematological domain, leucopenia stayed and thrombocytopenia remained at percentages of just below 50% and around 20, while

autoimmune hemolytic anemia had decreased to around 5 % in the more recent cohorts. Serosal manifestations also decreased from half in the ACR 1982 to one in eight in the EULAR/ACR 2019 criteria cohort, and neuropsychiatric manifestations fell to 5%. Since items were counted if present at any time, differences in disease duration could also influence sensitivity.

Limitations to inferences made about the specificity of criteria items relate to the case-mix and frequency of control diagnoses. This cohort included a large number of systemic autoimmune rheumatic diseases including Sjögren's syndrome, systemic sclerosis, rheumatoid arthritis and primary antiphospholipid antibody syndrome. This cohort also included controls with membranous nephritis, thyroiditis, autoimmune hepatitis, viral infections, tuberculosis, and sarcoidosis. However, the numbers of these control subjects were smaller. The relatively high proportions of patients with connective tissue diseases and patients with rheumatoid arthritis have implications for the performance of several of the items. Also, autoantibody testing was performed locally, resulting in variability in test performance. While we believe that the array of conditions is reflective of the typical differential diagnoses of SLE at our institutions, in other clinical settings rheumatoid arthritis and fibromyalgia may be the two most common considerations. This could influence item specificity and thus limit the generalizability of the data. In general, however, attribution to SLE only if there is no more likely alternative explanation should help specificity under any conditions. The same should hold true for limiting the criteria to higher specificity tests. With regard to undifferentiated connective tissue disease, also a usual consideration, two studies reassuringly show that a subset of these patients not only fulfil EULAR/ACR classification criteria, but then also apparently have true SLE (21,22).

In conclusion, data on the individual items comprising the new EULAR/ACR classification criteria for SLE demonstrate a wide range in sensitivity and a relatively uniform high level of specificity for all weighted items. Use of ANA as an obligatory entry criterion and the attribution rule contribute to the improved specificity.

### **Acknowledgements**

The classification criteria project has been jointly funded by EULAR and the ACR.

This research was supported in part by the Intramural Research Program of the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health

### **Conflicts of interest**

None reported.

### **Patient and Public Involvement**

SLE patient representatives were involved at every stage of the EULAR/ACR classification criteria project.

## References

- (1) Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. *Ann Rheum Dis* 2019; 78(9):1151-9.
- (2) Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R et al. 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. *Arthritis Rheumatol* 2019; 71(9):1400-12.
- (3) Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1997; 40(9):1725.
- (4) Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. *Arthritis Rheum* 2012; 64(8):2677-86.
- (5) Johnson SR, Brinks R, Costenbader KH, Daikh D, Mosca M, Ramsey-Goldman R et al. Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities . *Ann Rheum Dis* 2020; 79(10):1333-1339.
- (6) Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. *Arthritis Rheum* 1982; 25(11):1271-7.
- (7) Tedeschi SK, Johnson SR, Boumpas D, Daikh D, Dorner T, Jayne D et al. Developing and Refining New Candidate Criteria for Systemic Lupus Erythematosus Classification: An International Collaboration. *Arthritis Care Res (Hoboken )* 2018; 70(4):571-81.
- (8) Aringer M, Dorner T, Leuchten N, Johnson SR. Toward new criteria for systemic lupus erythematosus-a standpoint. *Lupus* 2016; 25(8):805-11.
- (9) Leuchten N, Hoyer A, Brinks R, Schoels M, Schneider M, Smolen J et al. Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data. *Arthritis Care Res (Hoboken)* 2018; 70(3):428-38.
- (10) Schmajuk G, Hoyer BF, Aringer M, Johnson SR, Daikh DI, Dorner T. Multicenter Delphi Exercise to Identify Important Key Items for Classifying Systemic Lupus Erythematosus. *Arthritis Care Res (Hoboken )* 2018; 70(10):1488-94.
- (11) Mosca M, Costenbader KH, Johnson SR, Lorenzoni V, Sebastiani GD, Hoyer BF et al. Brief Report: How Do Patients With Newly Diagnosed Systemic Lupus Erythematosus Present? A Multicenter Cohort of Early Systemic Lupus Erythematosus to Inform the Development of New Classification Criteria. *Arthritis Rheumatol* 2019; 71(1):91-8.
- (12) Leuchten N, Milke B, Winkler-Rohlfing B, Daikh D, Dorner T, Johnson SR et al. Early symptoms of systemic lupus erythematosus (SLE) recalled by 339 SLE patients. *Lupus* 2018; 27(9):1431-6.
- (13) Johnson SR, Khanna D, Daikh D, Cervera R, Costedoat-Chalumeau N, Gladman DD et al. Use of Consensus Methodology to Determine Candidate Items for Systemic Lupus Erythematosus Classification Criteria. *J Rheumatol* 2019; 46(7):721-6.



- (14) Touma Z, Cervera R, Brinks R, Lorenzoni V, Tani C, Hoyer BF et al. Associations among classification criteria items within systemic lupus erythematosus. *Arthritis Care Res (Hoboken)* 2020; 72(12):1820-1826.
- (15) Tedeschi SK, Johnson SR, Boumpas DT, Daikh D, Dorner T, Diamond B et al. Multicriteria decision analysis process to develop new classification criteria for systemic lupus erythematosus. *Ann Rheum Dis* 2019; 78(5):634-40.
- (16) Tani C, D'Aniello D, Delle SA, Carli L, Cagnoni M, Possemato N et al. Rhupus syndrome: assessment of its prevalence and its clinical and instrumental characteristics in a prospective cohort of 103 SLE patients. *Autoimmun Rev* 2013; 12(4):537-41.
- (17) Amezcua-Guerra LM, Springall R, Marquez-Velasco R, Gomez-Garcia L, Vargas A, Bojalil R. Presence of antibodies against cyclic citrullinated peptides in patients with 'rhupus': a cross-sectional study. *Arthritis Res Ther* 2006; 8(5):R144.
- (18) Johnson SR, Goek ON, Singh-Grewal D, Vlad SC, Feldman BM, Felson DT et al. Classification criteria in rheumatic diseases: a review of methodologic properties. *Arthritis Rheum* 2007; 57(7):1119-33.
- (19) Zayat AS, Mahmoud K, Md Yusof MY, Mukherjee S, D'Agostino MA, Hensor EMA et al. Defining inflammatory musculoskeletal manifestations in systemic lupus erythematosus. *Rheumatology (Oxford)* 2019; 58(2):304-12.
- (20) Fanouriakis A, Kostopoulou M, Alunno A, Aringer M, Bajema I, Boletis JN et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. *Ann Rheum Dis* 2019; 78(6):736-45.
- (21) Radin M, Schreiber K, Cecchi I, Bortoluzzi A, Crisafulli F, de Freitas CM et al. Impact of the new 2019 EULAR/ACR classification criteria for Systemic Lupus Erythematosus in a multicenter cohort study of 133 women with undifferentiated connective tissue disease. *Arthritis Care Res (Hoboken)* 2020; Jul 23 Epub. doi: 10.1002/acr.24391.
- (22) Drehmel KR, Erickson AR, England BR, Michaud KD, Sayles HR, Hearth-Holmes MP. Applying SLICC and ACR/EULAR systemic lupus erythematosus classification criteria in a cohort of patients with undifferentiated connective tissue disease. *Lupus* 2020; Nov 30 Epub. doi: 10.1177/0961203320976939.